Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon
Executive Summary
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
Chiesi Returns To Respiratory Roots With Affibody Pact
A busy start to the year sees the Italian firm adding to its respiratory portfolio by gaining access to the Swedish biotech’s investigational inhaled treatments.
Iveric Bio Building Ophthalmology Commercial Team Ahead Of First Launch
CEO Glenn Sblendorio talked to Scrip about the company's plans to transition into a commercial-stage company after completing an NDA submission for its geographic atrophy drug in December.
Three Years After US Filing, Biocon’s Bevacizumab Remains Out Of Reach
Following launches in other key developed markets, Biocon’s plans to break into the US bevacizumab market continue to be frustrated, with further bad news from the US Food and Drug Administration.